Safety May Decide Sprycel/Tesigna Battle For Gleevec Failures, Novartis Says

Novartis' investigational chronic myeloid leukemia therapy Tasigna (nilotinib) appears to not have the risk of pleural effusions seen with Bristol-Myers Squibb's Sprycel (dasatinib), Novartis Senior VP-Head of Development Alessandro Riva said June 5